现货大促销,价格低至8折起,量大更优惠,详细咨询客服
全部分类
全部分类
  • LY2157299
LY2157299的可视化放大

LY2157299

A TGF-β type 1 receptor kinase inhibitor

原价
¥425-5287
价格
340-4230
LY2157299的二维码

所有产品仅用于科学研究,我们不为任何个人用途提供产品和服务

询价有惊喜,量大更优惠 点击这里给我发消息

  • 库存: 现货
可选包装 >>>
首页
  • 货号: ajci20272
  • CAS: 700874-72-2
  • 别名: LY-2157299;LY 2157299
  • 分子式: C22H19N5O
  • 分子量: 369.42
  • 纯度: >98%
  • 溶解度: ≥ 18.45mg/mL in DMSO
  • 储存: Store at -20°C
  • 库存: 现货

Background

LY2157299 is a potent small-molecule antagonist that specifically inhibits Transforming Growth Factor-β receptor I (TβRI). LY2157299 is now under phase II clinical evaluation of its anti-carcinoma activity against hepatocellular carcinoma and glioblastoma1.


LY2157299 has been shown to inhibit β1-integrin activation and block the invasion and migration of hepatocellular cancer cells. In addition, multiple studies have revealed LY2157299 blocked the CTGF production and inhibited neoangiogenesis resulting suppression of hepatocellular carcinoma growth1.


LY2157299 has been reported to decrease phosphorylated Smad2 and Smad3 expression and inhibit the tumor growth in both human anaplastic carcinoma lung cell (Calu6) or human carcinoma breast cell (MX1) xenografted nude mice2.

参考文献:
1.?Giannelli G1, Villa E, Lahn M.Transforming Growth Factor-β as a Therapeutic Target in Hepatocellular Carcinoma. Cancer Res. 2014 Apr 1;74(7):1890-4. doi: 10.1158/0008-5472.CAN-14-0243. Epub 2014 Mar 17.
2.?Bueno L1, de Alwis DP, Pitou C, Yingling J, Lahn M, Glatt S, Trocóniz IFSemi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice. Eur J Cancer. 2008 Jan;44(1):142-50.

Protocol

Cell experiment: [1]

Cell lines

HLE and HLF cells

Preparation method

The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months.

Reaction Conditions

100 nM, 16 hours

Applications

HLE and HLF cells were allowed to migrate for 16 hours on fibronectin, vitronectin, laminin-5 and fibrinogen in the presence of increasing concentrations (1 nM, 10 nM and 100 nM) of LY2157299. LY2157299 significantly inhibited HLE and HLF migration on different ECM substrates. When testing the inhibition of Smad phosphorylation, two different HCC cell lines were pretreated for 16 hours with 100 nM of LY2157299 and then stimulated with 2 ng of TGF-β1 for 30 min. LY2157299 inhibited de novo phosphorylation of p-SMAD2 at the same efficiency in HLE and HLF after stimulation with TGF-β1. Besides that, increased expression of E-cadherin was observed in HLE and HLF cells after treatment for 48 hours.

Animal experiment: [2]

Animal models

Nude mice implanted with Calu6 or MX1 cells

Dosage form

Oral administration, 75mg/kg, twice a day

Applications

LY2157299 induced a 70% decrease in phosphorylated Smad (pSmad) for both types of cell lines. The time at which pSmad recovered 80% of baseline was approximately 6 h after administration.

Other notes

Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

参考文献:


[1] Dituri F, Mazzocca A, Peidrò F J, et al. Differential inhibition of the TGF-β signaling pathway in HCC cells using the small molecule inhibitor LY2157299 and the D10 monoclonal antibody against TGF-β receptor type II. PloS one, 2013, 8(6): e67109.


[2] Bueno L, de Alwis D P, Pitou C, et al. Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-β kinase antagonist, in mice. European journal of cancer, 2008, 44(1): 142-150.

动态评分

0.0

没有评分数据
没有评价数据
一键回到顶部
展开 收缩
安捷凯在线客服